Edition:
United Kingdom

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

3.96USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$3.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,251
52-wk High
$8.80
52-wk Low
$3.65

Latest Key Developments (Source: Significant Developments)

FDA Grants Qidp And Fast Track Designations To Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Cidara Therapeutics Inc ::FDA GRANTS QIDP AND FAST TRACK DESIGNATIONS TO CIDARA THERAPEUTICS’ REZAFUNGIN PROPHYLAXIS DEVELOPMENT PROGRAM.CIDARA THERAPEUTICS INC - REZAFUNGIN DESIGNATED FOR PREVENTION OF INVASIVE FUNGAL INFECTIONS IN ADULTS UNDERGOING BONE MARROW TRANSPLANTATION.CIDARA - PLANS TO COMMENCE PHASE 3 CLINICAL TRIAL OF REZAFUNGIN IN PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION IN Q1 2019.  Full Article

Cidara Enters Into Amendment To Its Loan, Security Agreement With Pacific Western Bank
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS - ENTERED INTO A SECOND AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH PACIFIC WESTERN BANK DATED AS OF OCTOBER 3, 2016.CIDARA THERAPEUTICS SAYS UNDER AMENDMENT, MATURITY DATE OF AGREEMENT EXTENDED TO JAN 3, 2022, INTEREST-ONLY PERIOD EXTENDED THROUGH JULY 31, 2019.CIDARA - INTEREST-ONLY PERIOD OF AGREEMENT TO BE EXTENDED THROUGH OCT 31, 2019 UNDER CERTAIN CONDITIONS.  Full Article

Cidara Therapeutics Inc To Offer Up To 12.5 Mln Shares By Selling Stockholders - SEC Filing
Thursday, 21 Jun 2018 

June 21 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Cidara Therapeutics Says Entered First Amendment To Loan And Security Agreement With Pacific Western Bank
Monday, 18 Jun 2018 

June 18 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS INC - ON JUNE 13, ENTERED FIRST AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH PACIFIC WESTERN BANK DATED AS OF OCTOBER 3, 2016.CIDARA - AMENDMENT RESETS COVENANT TO REQUIRE CO TO ACHIEVE POSITIVE DATA FROM PART B OF THE STRIVE TRIAL ON OR PRIOR TO JULY 31, 2019 - SEC FILING.  Full Article

Cidara Therapeutics Files For Stock Shelf Of Up To $10 Mln
Monday, 21 May 2018 

May 21 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $10 MILLION – SEC FILING.  Full Article

Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS.  Full Article

Cidara reports qtrly ‍basic and diluted net loss per share $0.73​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::Cidara provides corporate update and reports third quarter 2017 financial results.Cidara Therapeutics Inc - qtrly ‍basic and diluted net loss per share $0.73​.Cidara Therapeutics Inc - qtrly ‍total operating expenses $12.2 million versus $12.3 million.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.  Full Article